AKTX | Akari Therapeutics, Plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.9504 - 1.0138
52 Week Range	0.9000 - 4.40
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	36,858
Average Volume	43,287
Shares Outstanding	12,782,527
Market Cap	12,399,051
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-01-06

Valuation
Profitability
Growth
Health
P/E Ratio	-0.38
Forward P/E Ratio	N/A
EPS	-2.58
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6
Country	UK
Website	AKTX

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.

AKTX's peers: AIM, ARMP, ANEB, SCPS, PCSA, SLRX, AXLA, MGTA, HSTO, PULM, CAPR, DFFN, SLNO, ONCR, SONN, LABP, ARTL, BPTH, BRTX, COCP, CYCC, ABVC, GTBP, MBIO, MBRX, PTN, TPST, VYNE

*Chart delayed

Analyzing fundamentals for AKTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see AKTX Fundamentals page.

Watching at AKTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AKTX Technicals page.